{
    "nct_id": "NCT03239873",
    "official_title": "A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Passage Extension 34 (PE34) Process Administered Concomitantly With M-M-R™ II",
    "inclusion_criteria": "* Negative clinical history for varicella, herpes zoster, measles, mumps, and rubella\nHealthy volunteers allowed\nMust have minimum age of 12 Months\nMust have maximum age of 23 Months",
    "exclusion_criteria": "* Received any measles, mumps, rubella, or varicella vaccine at any time prior to the study, or is anticipated to receive any of these vaccines outside the study\n* Any congenital or acquired immune deficiency, neoplastic disease, or depressed immunity\n* Received systemic immunomodulatory steroids within 3 months prior to entering the study or is expected to receive them during the course of the study\n* History of allergy or anaphylactic reaction to neomycin, gelatin, sorbitol, egg proteins, chicken proteins, or any component of VARIVAX® or M-M-R II®\n* Has any blood dyscrasias, leukemia, lymphoma, or other malignant neoplasm affecting the bone marrow or lymphatic systems\n* Received salicylates within 14 days prior to study vaccination\n* Exposed to varicella, herpes zoster, measles, mumps, or rubella in the 4 weeks prior to study vaccination\n* Received immune globulin, a blood transfusion, or blood-derived products within 5 months prior to study vaccination\n* History of seizure disorder, including febrile seizure\n* Fever illness (>=102.2 °F [39.0 °C] within 72 hours prior to study vaccination\n* History of thrombocytopenia\n* Born to a human immunodeficiency virus (HIV)-infected mother\n* Has a diagnosis of active untreated tuberculosis\n* Participated in any other clinical trial (other than a surveillance study) within 30 days prior to study enrollment.",
    "miscellaneous_criteria": ""
}